Utdelning 2023

I år kan Radiumhemmets Forskningsfonder dela ut 80 miljoner kronor till patientnära cancerforskning – tack till alla er som bidragit med gåvor!

Årets stöd har delats ut till forskningsprojekt inom följande områden: barncancer, blodcancer, bröstcancer, gynekologisk cancer, hudcancer, kolorektalcancer, levercancer, lungcancer, lymfom, matstrups- och magsäckscancer, prostatacancer, sarkom, urinblåsecancer och ärftlig cancer.

Stöd har även tilldelats projekt inriktade på tumörers egenskaper, diagnostik och behandling såsom cancervaccin, immunterapi och strålbehandling.

För att gynna patientnära cancerforskning även på längre sikt finansierar vi också professorstjänster samt forskningstid för läkare och doktorander.

Dessutom främjar vi att nya behandlingar snabbare kommer patienter till nytta, genom stöd till bland annat Centrum för kliniska cancerstudier vid Karolinska Universitetssjukhuset.

Tack för alla gåvor som bidragit till detta!

Årets projektanslag

Följande forskare och projekt har beviljats stöd:

  • Renske Altena, docent – HER2-Ex PET-studien: Förfinad Behandlingsval och Ökad av Biologisk Förståelse vid HER2-låg Bröstcancer med användning av HER2-PET.
  • Rimma Axelsson, professor – [11C]AZ14193391 – PET as a selection tool for treatment with PARP inhibitors in patients with ovarian cancer.
  • Svetlana Bajalica Lagercrantz, professor – Predisposition, prediktion och prevetion av ärftlig cancer orsakad av medfödd skada i TP53.
  • Mikael Benson, professor – Digital twins for individualised diagnostics and treatment of patients with pancreatic cysts.
  • Mikael Björnstedt, professor – Redoxenzymer och selenföreningar i diagnostik och behandling av resitent tumörsjukdom.
  • Johannes Blom, docent – Surgery versus Endoscopic Resection for Incompletely Removed Early Colon Cancer randomized controlled trial (The SCAR trial).
  • Mattias Carlsten, docent  – Establishing long-lived tumor homing NK cells as a cell therapy product that can induce durable remissions in patients with myeloid leukemia.
  • Kamila Czene, professor – Application of precision health concept for improvement of mammography screening for breast cancer.
  • Jana de Boniface, docent – Physical exercise during neoadjuvant chemotherapy for breast cancer as a means to increase pCR rates: the randomized Neo-ACT trial.
  • Luigi De Petris, med. dr – Clinical factors of importance for immunotherapy in non-small cell (NSCLC), and biomarker studies in relation to treatment pathways in small-cell lung.
  • Joakim Dillner, professor – Long-term follow-up of cancer preventive trials targeting Human Papillomavirus (HPV).
  • Lars Egevad, professor – Artificiell intelligens och genetik för diagnostik och prognostik av prostatacancer.
  • Simon Ekman, professor – Resistance to Targeted Therapies in Non-Small Cell Lung Cancer – Novel Diagnostic and Therapeutic Approaches in Precision Cancer Medicine.
  • Elisabeth Epstein, professor – AI driven ultrasound diagnostics and circulating tumor DNA improve ovarian cancer detection – multicenter validation and clinical implementation.
  • Henrik Falconer, docent – The BIOMEC trial: A randomized trial to determine the efficacy of biomarker staging in presumed early-stage endometrial cancer.
  • Theodoros Foukakis, docent – Integrative machine learning models to predict response to neoadjuvant therapy in breast cancer.
  • Irma Fredriksson, med. dr – Randomiserade studier av lokal och systemisk behandling av primär bröstcancer.
  • Jonas Fuxe, docent – EMT as a novel biomarker in precision-based medicine to identify breast cancer patients with increased risk of developing metastatic disease.
  • Susanne Gabrielsson, professor – Extracellular vesicles as disease biomarkers and therapeutic targets in urinary bladder cancer.
  • Kristina Gemzell Danielsson, professor – The impact of Selective Progesterone Receptor Modulators as prevention of breast- and ovarian cancer.
  • Marco Gerling, med. dr – Blood-derived liver-centric markers to improve treatment decisions in liver metastases (BLOOM).
  • Felix Haglund, docent – Fortsatta genetiska studier av sarkom.
  • Hannes Hagström, docent – Förbättrad prediktion och behandling av levercancer – populationsbaserade studier.
  • Olli Kallioniemi, professor – Data-driven hallmarks (DDHM) as a new rational base for precision medicine interventions: Acute myeloid leukemia (AML) as a proof of concept.
  • Taras Kreslavskiy, fil. dr – Antigen recognition by tumor-infiltrating gamma delta T lymphocytes in neuroblastoma.
  • Jesper Lagergren, professor – Oesophago-gastric cancer: Prevention, treatment and follow-up.
  • Pernilla Lagergren, professor – Towards improved survivorship among oesophageal and gastric cancer patients.
  • Catharina Larsson, professor – Molecular, functional and clinical aspects of endocrine tumor development – a precision medicine approach.
  • Ola Larsson, docent – Continued identification of breast cancer subtypes defined by post-transcriptional regulation of gene expression.
  • Andreas Lennartsson, docent – Deciphering regulatory RNA circuits mediated by extracellular vesicles to predict and target Acute Myeloid Leukemia.
  • Johan Lindberg, tekn. dr – Liquid biopsies in metastatic prostate cancer.
  • Weng-Onn Lui, docent – Identification of biomarkers and mechanisms of immune evasion in Merkel cell carcinoma.
  • Giuseppe Masucci, docent – Prediktiva faktorer för behandlingsvinst och immunterapitoxicitet genom användning av artificiell intelligens.
  • Stephan Mielke, professor – Armed gamma delta-TILs to combat ovarian cancer: Linking precision diagnostics to ATMP development.
  • Robert Månsson, fil. dr – Charting the gene regulatory landscape, etiology, and genetics of multiple myeloma.
  • Caroline Nordenvall, docent – Metastatic colorectal cancer and the influence of tumor immunology and gut-microbiome – future aspects in precision medicine?
  • Maria Pernemalm, docent – Improving early lung cancer diagnosis – a multimodal approach.
  • Georgios Rassidakis, professor – Identification and prognostic significance of novel genetic and anti-tumor immune response biomarkers of T-cell lymphomas in the era of immunotherapy.
  • Kenny Rodriguez-Wallberg, professor – Oncofertility: Nationwide collaborative studies on fertility preservation and pregnancy during cancer.
  • Margaret Sallberg Chen, professor – Harnessing Oral Microbiome & Immune Repertoire for Personalized Treatment and mRNA Vaccination in Cancer Patients.
  • Birgitta Sander, professor – Molecular pathogenesis of B-cell lymphomas with focus on novel therapy targets and individualized treatment.
  • Olle Sangfelt, docent – SCF ubiquitin ligases as molecular targets sustaining genomic integrity and antitumor immunity.
  • Dhifaf Sarhan, docent – Study the therapeutic potential of adaptive NK cells in solid tumors.
  • Susanne Schlisio, docent – Neuroblastoma och paraganglioma cellstadie dynamik och plasticitet vid tumörbildning och terapiresistens.
  • Brinton Seashore-Ludlow, fil. dr – A functional precision medicine approach to improve treatment of ovarian cancer.
  • Peter Strang, professor – Kostnader för cancervård och läkemedel under de sista månaderna – rimliga och jämlika?
  • Karin Sundström, med. dr – Humant PapillomVirus bland Svenska kvinnor med cERVIXcancer (HPV-SERVIX).
  • Anders Ullén, professor – Translational studies of advanced and metastatic bladder cancer – from identification of new biomarkers and treatment strategies to clinical trials.
  • Alexander Valdman, docent – Personalized Radiotherapy for Rectal Cancer.
  • Lisa Westerberg, fil. dr – Understanding the immune cell dysfunction in pediatric lymphoma.
  • Klas Wiman, professor – Further studies of the mutant p53-targerting compound APR-246 with the aim of improved cancer therapy.
  • Dawei Xu, docent – Rollen av GABPA i endogen retrovirusrepression och telomerasaktivering: implikationer i onko-immunitet och precisionsimmunterapi.